Skip to main content
OpenTrials
Completed

NCT Number: NCT04882605

KIR Sequencing and Typing for Allograft in Nancy

The use of haploidentical donors for aHSCT has greatly increased this past decade leading to a major paradigm shift: while finding 10/10 HLA-matched donors represented the prior difficulty for decades, the current problem is about finding the best haploidentical donor among several potential ones. The prediction of NK cells alloreactivity toward leukemic cells provides promising perspectives, although the underlying biological processes remain unclear. To date, many prediction models based on KIR and MHC genotyping have been designed and used across studies, which contribute to blur clinical conclusions.

The investigators hypothesized that the diversity of models used to predict NK alloreactivity in aHSCT could partly be responsible for the current literature discrepancies. The main objective of this work consisted of applying the major KIR-based prediction models in D/R couples undergoing aHSCT in different fashions - with MSD and haploidentical donors - to describe their heterogeneity and potential correlations. As clinical data were available for these two cohorts, the investigators described correlations that could be assessed between the scoring strategies and the clinical outcomes.

As suspected, it was highlighted that the different scoring strategies greatly impact the assessment of alloreactivity within D/R couples. As an example, two broadly used scoring strategies - educational models and missing-ligand models - show clear opposite predictions. Moreover, some scoring strategies seem to be better adapted to genoidentical or haploidentical cohorts, whereas others are robust across the different cohorts. Concerning the clinical-biological correlations, it was highlighted that (i) each scoring strategy is differentially associated to the different outcomes (ii) the different scoring strategies predict one particular outcome with different efficacy (iii) the D/R compatibility greatly impacts the pertinence of the scoring strategy.

This work therefore contributes to unravel the KIR-based alloreactivity prediction of NK cells in aHSCT. This would help to overcome the current literature discrepancies in this field as in making new hypotheses to better understand and predict NK alloreactivity to further develop its use in medical practice.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

COHORT 1 = Matched Sibling Donors couples (MSD couples) INCLUSION CRITERIA

  • recipient of HSCT selected from the French national database CRYOSTEM
  • adult patients (18-50 years old)
  • transplanted in first remission
  • receiving myeloablative conditioning without anti-thymoglobulin
  • 16 couples without any sign of GVH (8 males and 8 females)
  • 16 couples with aGVH without cGVH
  • 9 couples with cGVH without aGVH
  • 9 couples with both cGVH and aGVH. EXCLUSION CRITERIA
  • insufficient DNA material after Miltenyi extraction

COHORT 2 = Haploidentical couples INCLUSION CRITERIA

  • patient undergoing a haploidentical HSCT in the Hematology Department of Nancy's University Hospital, Lorraine, France (French Minister registration number : DC-2020-4068) EXCLUSION CRITERIA
  • insufficient DNA material after Miltenyi extraction (7 MSD couples)

Treatment and study plan

MHC typing

Genetic

Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.

KIR typing

Genetic

Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.

Assessment of KIR-based prediction scores

Genetic

Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores

Primary outcomes

  1. Describe the heterogeneity of the major KIR-based prediction models in assessing alloreactivity

    Time frame: At inclusion

  2. Describe the potential correlations between a KIR-based prediction models and post-allograft outcomes

    Time frame: at least 4 months

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Collaborators

  • University of Cambridge

Registry information

Official study title

Application of the Major Predictive Scoring Strategies Assessing KIR-based NK Alloreactivity to Donor/Recipient Couples

Acronym: KIR-STAN

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
May 12, 2021
Registry last updated
May 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.